Myeloid malignancies with acquired trisomy 21 as the sole cytogenetic change are clinically highly variable and display a heterogeneous pattern of copy number alterations and mutations*

Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression

(2011) T. Klampfl et al.   BLOOD

An accumulation of cytogenetic and molecular genetic events characterizes the progression from MDS to secondary AML: an analysis of 38 paired samples analyzed by cytogenetics, molecular mutation analysis and SNP microarray profiling

(2011) J Flach et al.   LEUKEMIA

Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia

(2010) B. Parkin et al.   BLOOD

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

(2010) D. Grimwade et al.   BLOOD

Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells

(2010) Nina Larsson et al.   CANCER GENETICS AND CYTOGENETICS

Bone marrow karyotypes in 94 children with acute leukemia

(2010) S. Heim et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

The idic(X)(q13) in myeloid malignancies: breakpoint clustering in segmental duplications and association with TET2 mutations

(2010) K. Paulsson et al.   HUMAN MOLECULAR GENETICS

Cytogenetics of Childhood Acute Myeloid Leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12

(2010) Christine J. Harrison et al.   JOURNAL OF CLINICAL ONCOLOGY

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes

(2010) Gorica Nikoloski et al.   NATURE GENETICS

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

(2010) Thomas Ernst et al.   NATURE GENETICS

Trisomic dose of several chromosome 21 genes perturbs haematopoietic stem and progenitor cell differentiation in Down's syndrome

(2010) S De Vita et al.   ONCOGENE

AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms

(2009) Y. Ding et al.   BLOOD

Trisomy of Erg is required for myeloproliferation in a mouse model of Down syndrome

(2009) A. P. Ng et al.   BLOOD

Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms

(2009) A. M. Jankowska et al.   BLOOD

Genome-wide DNA-mapping of CD34+ cells from patients with myelodysplastic syndrome using 500K SNP arrays identifies significant regions of deletion and uniparental disomy

(2009) Daniel Nowak et al.   EXPERIMENTAL HEMATOLOGY

Novel TET2 Mutations Associated With UPD4q24 in Myelodysplastic Syndrome

(2009) Azim M. Mohamedali et al.   JOURNAL OF CLINICAL ONCOLOGY

Acquired mutations in TET2 are common in myelodysplastic syndromes

(2009) Saskia M C Langemeijer et al.   NATURE GENETICS

Mutation inTET2in Myeloid Cancers

(2009) François Delhommeau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trisomy 21 in patients with acute leukemia

(2008) Yizhi Cheng et al.   AMERICAN JOURNAL OF HEMATOLOGY

RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance

(2008) C. Roche-Lestienne et al.   BLOOD

AML1 mutations induced MDS and MDS/AML in a mouse BMT model

(2008) N. Watanabe-Okochi et al.   BLOOD